RNR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
RenaissanceRe Holdings Ltd (RNR) is not a strong buy for a beginner, long-term investor at this time. The stock is currently experiencing negative momentum, with technical indicators showing bearish trends, insider selling activity, and no significant positive catalysts. Additionally, the company's recent financial performance shows a significant decline in net income and EPS, which raises concerns about growth potential. Analyst ratings suggest the stock is fairly valued, with limited upside potential. Given the user's preference for long-term investment and the current market conditions, it is better to hold off on purchasing RNR at this time.
The MACD histogram is negative and expanding (-1.796), indicating bearish momentum. RSI is at 32.135, which is neutral but close to oversold territory. Moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 300.75, with support at 290.065 and resistance at 307.355. Overall, the technical indicators suggest a bearish trend.
No significant positive catalysts identified. The company's revenue increased by 3.41% YoY in Q4 2025, but this is overshadowed by other negative factors.
Insiders are selling heavily, with a 432.14% increase in selling activity over the last month. Analysts have downgraded the stock to Neutral or Equal Weight, citing valuation concerns and increased competition. The company's net income and EPS have significantly declined YoY. Technical indicators are bearish, and no recent congress trading data or influential figure activity supports the stock.
In Q4 2025, revenue increased by 3.41% YoY to $2.93 billion. However, net income dropped by -477.23% YoY to $739.12 million, and EPS fell by -530.59% YoY to 16.75. Gross margin remained unchanged. The financial performance highlights significant profitability challenges despite modest revenue growth.
Analysts have mixed ratings, with most maintaining Neutral or Hold stances. Recent downgrades cite valuation concerns and limited growth potential. Price targets range from $290 to $333, with the current price of $293.18 near the lower end of this range, suggesting limited upside.
